



UR
MEDICINE

Labs

HIV-1/2 Qualitative NAAT: New Assay for Newborn/Infant HIV Diagnosis and for Patients on PrEP

Date: October 5th, 2023

Effective Date: October 18th, 2023

UR Medicine Labs will begin performing a qualitative HIV-1/2 nucleic acid amplification test (NAAT) intended for: (1) the management of patients receiving PrEP (pre-exposure prophylaxis), and (2) diagnosis of HIV-1/2 in newborns/infants (<18 months).

For routine HIV diagnostic testing (i.e. for patients ≥ 18 months), providers should continue ordering the HIV-1/2 Antigen/Antibody Screen with Confirmation (test code: HV12C). Consistent with current CDC recommendations for the diagnosis of HIV, the HIV-1/2 Antigen/Antibody Screen with Confirmation includes a 4th-generation HIV-1/2 Antigen/Antibody immunoassay and subsequent HIV-1/2 Antibody Confirmation.

The HIV-1/2 Qualitative NAAT may be ordered using the following test codes. For patients receiving PrEP, providers have the option of ordering the HIV-1/2 PrEP Panel, which includes both the HIV-1/2 Qualitative NAAT and the HIV-1/2 Antigen/Antibody Screen with Confirmation.

Test name: HIV-1/2 Qualitative NAAT

Test code: HV12Q

Specimen: Plasma (10 mL lavender [EDTA] tube)

Panel name: HIV-1/2 PrEP Panel

Test code: HIVPP

Includes: HIV-1/2 Qualitative NAAT and HIV-1/2 Antigen/Antibody Screen with Confirmation.

Specimen: Plasma (10 mL lavender [EDTA] tube) AND Serum (Serum Separator Tube)

For questions or additional information, please contact Lindsay Ryan-Muntz, Serology/Immunology Supervisor, Lindsay_Ryan-Muntz@URMC.Rochester.edu or Andrew Cameron, PhD.

From: Andrew Cameron, PhD D(ABMM)

Assistant Director, Clinical Microbiology, UR Medicine Labs

University of Rochester Medical Center

Phone: (585) 276-4674

E-mail: andrew_cameron@urmc.rochester.edu